Bausch Health Cos (BHC) Stock Price, News & Analysis

Company Overview

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Key Stats

• Today's Range: $7.45 to $7.72
• 50-Day Range: $5.71 to $8.34
• 52-Week Range: $4.25 to $9.85
• Volume: 1.88 million shs
• Average Volume: 4.52 million shs
• Market Capitalization: $2.77 billion
• P/E Ratio: 28.77
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

Bausch Health Cos Stock Analysis - MarketRank™

Bausch Health Cos scored higher than 84% of companies evaluated by MarketBeat, and ranked 184th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Hold

Consensus Rating

Bausch Health Cos has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Bausch Health Cos has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 5.67%

Earnings Growth

Earnings for Bausch Health Cos are expected to grow by 5.67% in the coming year, from $4.41 to $4.66 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bausch Health Cos is 28.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.44.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bausch Health Cos is 28.77, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.33.

Price to Book Value per Share Ratio

Bausch Health Cos has a P/B Ratio of 18.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.50% of the float of Bausch Health Cos has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Cos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Cos has recently decreased by 2.02%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bausch Health Cos does not currently pay a dividend.

Dividend Growth

Bausch Health Cos does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.0 / 5
• Environmental Score: -1.42

Percentage of Shares Shorted

2.50% of the float of Bausch Health Cos has been sold short.

Short Interest Ratio / Days to Cover

Bausch Health Cos has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bausch Health Cos has recently decreased by 2.02%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.10

News Sentiment

Bausch Health Cos has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Bausch Health Cos this week, compared to 5 articles on an average week.

Search Interest

35 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 35% compared to the previous 30 days.

MarketBeat Follows

6 people have added Bausch Health Cos to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Bausch Health Cos insiders have bought more of their company's stock than they have sold. Specifically, they have bought $369,628,560.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 8.05% of the stock of Bausch Health Cos is held by insiders.

Percentage Held by Institutions

78.65% of the stock of Bausch Health Cos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BHC Stock Analysis - Frequently Asked Questions

How have BHC shares performed this year?

Bausch Health Cos' stock was trading at $8.06 at the beginning of 2025. Since then, BHC stock has decreased by 7.2% and is now trading at $7.4810.

How were Bausch Health Cos' earnings last quarter?

Bausch Health Cos Inc. (NYSE:BHC) posted its quarterly earnings data on Wednesday, July, 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by $0.07. The business earned $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative trailing twelve-month return on equity of 852.36%.
Read the conference call transcript.

Who are Bausch Health Cos' major shareholders?

Top institutional investors of Bausch Health Cos include Goldentree Asset Management LP (9.25%), Paulson & CO. Inc. (8.86%), Nomura Holdings Inc. (5.81%) and Maple Rock Capital Partners Inc. (2.11%). Insiders that own company stock include John Paulson and Seana Carson.
View institutional ownership trends.

How do I buy shares of Bausch Health Cos?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bausch Health Cos own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bausch Health Cos investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Tesla (TSLA), Bristol Myers Squibb (BMY) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 8/24/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - GENERIC DRG
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:BHC
• CIK: 885590
• Web: www.bauschhealth.com
• Phone: (514) 744-6792
• Fax: 514-744-6272
• Employees: 20,700
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Bausch Health Cos: $9.00
• High Price Target: $10.00
• Low Price Target: $8.00
• Potential Upside/Downside: +20.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.26
• Trailing P/E Ratio: 28.77
• Forward P/E Ratio: 1.70
• P/E Growth: N/A
• Net Income: -$46 million
• Net Margins: 0.99%
• Pretax Margin: 2.85%
• Return on Equity: -852.36%
• Return on Assets: 5.25%

Debt

• Debt-to-Equity Ratio: 141.90
• Current Ratio: 1.31
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $9.63 billion
• Price / Sales: 0.29
• Cash Flow: $7.71 per share
• Price / Cash Flow: 0.97
• Book Value: $0.40 per share
• Price / Book: 18.70

Miscellaneous

• Outstanding Shares: 370,130,000
• Free Float: 340,331,000
• Market Cap: $2.77 billion
• Optionable: Optionable
• Beta: 0.41